《華爾街日報》稱，隨著施樂打印機和復(fù)印機業(yè)務(wù)的不斷萎縮，迫于壓力，施樂正在尋找新的業(yè)務(wù)增長源，并與日本相機制造商富士控股談判，內(nèi)容包括對施樂進(jìn)行收購等。

由于施樂難以在辦公打印機需求低迷的環(huán)境中重振其傳統(tǒng)業(yè)務(wù)，這家總部位于康涅狄格州諾沃克的公司成為了激進(jìn)投資者卡爾·伊坎的目標(biāo)。與此同時，富士正努力精簡其復(fù)印機業(yè)務(wù)，而將更多的精力放在了文件解決方案服務(wù)領(lǐng)域。

施樂是復(fù)印機行業(yè)的領(lǐng)軍者，而富士旗下已經(jīng)有一家50年歷史的復(fù)印機合資企業(yè)（位于東京），專注于亞太市場，包括日本和中國，而施樂則主攻世界其他地區(qū)。

華爾街在上周三的報告中援引了來自于知情人士的消息。據(jù)其中一位人士透露，富士無意全盤收購施樂。

施樂拒絕對此置評。富士表示其不會對投機性報道置評。

施樂的市值約為77億美元，而富士的市值約為220億美元。

去年12月，也就是在新任命4名董事的第二天，伊坎在致股東的一封公開信中寫道，由于施樂在推出新品、提升營收方面行動緩慢，因此公司“迫切”需要新的領(lǐng)導(dǎo)層。他目前持有施樂9.7%的股份，是其最大的股東。

施樂于2016年剝離了其業(yè)務(wù)流程外包部門，并拆分為兩家獨立上市公司。

在《華爾街日報》發(fā)布這一報道之后，富士東京股價下跌至4,724日元，跌幅1.8%，同期日本大盤的跌幅為0.3%。

復(fù)印機合資公司富士施樂成立于1962年，如今占據(jù)富士銷售和運營利潤的近半壁江山。

富士一直試圖在其不斷萎縮的照相膠卷業(yè)務(wù)之外尋找業(yè)務(wù)增長點，這也推動了公司在其他一些領(lǐng)域的收購動機，例如再生醫(yī)藥領(lǐng)域。

富士過去的交易包括2015年收購美國生物科技公司Cellular Dynamics International，后者是一家制造人類誘導(dǎo)性多能干細(xì)胞(iPS)和組織細(xì)胞的公司。

去年8月，富士表示計劃在未來三年內(nèi)花費5000億日元（44.9億美元）用于戰(zhàn)略收購。(財富中文網(wǎng))

譯者：馮豐

審稿：夏林

?

Xerox, under pressure to find new growth sources amid shrinking demand for its printer and copier business, is in talks for a deal with Japanese camera maker Fujifilm Holdings that could include a change in control of Xerox, the Wall Street Journal reported.

Norwalk, Conn.-based Xerox been targeted by activist investor Carl Icahn as it struggles to reinvent its legacy business amid waning demand for office printing. Fujifilm is trying to streamline its copier business with a larger focus on document solutions services.

Xerox, which pioneered photocopiers, and Fujifilm already have a five-decade old Tokyo-based copier joint venture focusing on the Asia Pacific region including Japan and China, leaving Xeroxto cover the rest of the world.

The Journal report on last?Wednesday cited people familiar with the matter. It also said a full takeover of Xerox is not on the table, citing one of the people.

Xerox declined to comment. Fujifilm said it would not comment on speculative reports.

Xerox has a market value of about $7.7 billion, while Fujifilm is valued at around $22 billion.

Xerox “desperately” needed new leadership as it was slow to launch new products and increase revenue, Icahn wrote in an open letter to shareholders in December, a day after nominating four members to the board. He is Xerox‘s biggest shareholder with a stake of 9.7%.

Xerox spun off its business process outsourcing unit in 2016 and separated into two independent, publicly traded companies.

Fujifilm shares fell 1.8% in Tokyo to 4,724 yen per share following the Journal report, while the broader Japanese market slipped 0.3%.

The copier joint venture, Fuji Xerox, was created in 1962 and now accounts for nearly half of Fujifilm’s sales and operating profit.

Fujifilm has been seeking growth outside its shrinking photographic film business, stepping up its acquisition drive in areas such as regenerative medicine.

Past deals include the 2015 purchase of Cellular Dynamics International, a U.S. biotechnology firm that makes human-induced pluripotent stem (iPS) cell lines and tissue cells.

Last August, it said it aimed to spend 500 billion yen ($4.49 billion) in strategic acquisitions over three years.